MX2024006777A - Davunetida (nap) para el tratamiento específico según el sexo contra enfermedades. - Google Patents

Davunetida (nap) para el tratamiento específico según el sexo contra enfermedades.

Info

Publication number
MX2024006777A
MX2024006777A MX2024006777A MX2024006777A MX2024006777A MX 2024006777 A MX2024006777 A MX 2024006777A MX 2024006777 A MX2024006777 A MX 2024006777A MX 2024006777 A MX2024006777 A MX 2024006777A MX 2024006777 A MX2024006777 A MX 2024006777A
Authority
MX
Mexico
Prior art keywords
diseases
sex
treatment
specific treatment
nap
Prior art date
Application number
MX2024006777A
Other languages
English (en)
Spanish (es)
Inventor
Illana Gozes
Guy Shapira
Alexandra Lobyntseva
Gidon Karmon
Noam Shomron
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Publication of MX2024006777A publication Critical patent/MX2024006777A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2024006777A 2021-12-14 2022-12-13 Davunetida (nap) para el tratamiento específico según el sexo contra enfermedades. MX2024006777A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163289174P 2021-12-14 2021-12-14
US202263306146P 2022-02-03 2022-02-03
PCT/IL2022/051314 WO2023112025A1 (en) 2021-12-14 2022-12-13 Nap for sex-specific treatment of diseases

Publications (1)

Publication Number Publication Date
MX2024006777A true MX2024006777A (es) 2024-08-06

Family

ID=86773996

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006777A MX2024006777A (es) 2021-12-14 2022-12-13 Davunetida (nap) para el tratamiento específico según el sexo contra enfermedades.

Country Status (9)

Country Link
US (1) US20250312408A1 (https=)
EP (1) EP4447994A4 (https=)
JP (1) JP2025501458A (https=)
KR (1) KR20240135692A (https=)
AU (1) AU2022410066A1 (https=)
CA (1) CA3240138A1 (https=)
IL (1) IL313226A (https=)
MX (1) MX2024006777A (https=)
WO (1) WO2023112025A1 (https=)

Also Published As

Publication number Publication date
EP4447994A1 (en) 2024-10-23
IL313226A (en) 2024-07-01
CA3240138A1 (en) 2023-06-22
WO2023112025A1 (en) 2023-06-22
AU2022410066A1 (en) 2024-07-25
KR20240135692A (ko) 2024-09-11
JP2025501458A (ja) 2025-01-22
US20250312408A1 (en) 2025-10-09
EP4447994A4 (en) 2026-01-07

Similar Documents

Publication Publication Date Title
WO2018112446A3 (en) Use of apoe4 motif-mediated genes for diagnosis and treatment of alzheimer's disease
GEP20257840B (en) Tyk2 pseudokinase ligands
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MY200962A (en) Amide Derivatives As Nav1.7 And Nav1.8 Blockers
MX394241B (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
DE60219917D1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
GEP20207149B (en) Allosteric modulators of nicotinic acetylcholine receptors
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
PH12019550236A1 (en) Detection of misfolded tau protein
MA41758B1 (fr) Procédés de traitement de l'infertilité
EA201390710A1 (ru) Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения
PH12016501993A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
MX2021007425A (es) Derivados heterociclicos como bloqueadores de nav1.7 y nav1.8.
MX378607B (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
JOP20200272A1 (ar) مُعدّلات تفارغية سبيروبيريدين لمستقبلات أستيل كولين نيكوتينية
MY209459A (en) Peptide conjugates of microtubule-targeting agents as therapeutics
PH12021551419A1 (en) New conjugated nucleic acid molecules and their uses
MX2024006777A (es) Davunetida (nap) para el tratamiento específico según el sexo contra enfermedades.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
SA521422315B1 (ar) ببتيدات لعلاج مرض السكرى والاضطربات ذات الصلة والوقاية منها
MA50034B1 (fr) Composition de stimulation ovarienne contrôlée